Therefore, this study aims to explore whether serum GFAP can serve as a reliable biomarker for assessing cross-sectional vasculitis activity in AAV patients, with the goal of enhancing both objectivity and convenience in clinical evaluations. The gene discussed is GFAP; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.